quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:26:11·49d
SECFiling
NextCure Inc. logo

SEC Form 10-K filed by NextCure Inc.

NXTC· NextCure Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • NXTC
    NextCure Inc.
    Health Care

Recent analyst ratings

  • Nov 7UpdateLadenburg Thalmann$18.00
  • Nov 4UpdateLadenburg Thalmann-
  • Mar 1UpdateLadenburg Thalmann$16.00
  • Nov 5UpdateNeedham$14.00

Related

  • PR2d
    NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
  • PR16d
    NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
  • PR23d
    NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
  • SEC49d
    NextCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR49d
    NextCure Provides Business Update and Reports Full Year 2025 Financial Results
  • SEC49d
    Amendment: SEC Form SCHEDULE 13D/A filed by NextCure Inc.
  • SEC69d
    Amendment: SEC Form SCHEDULE 13G/A filed by NextCure Inc.
  • INSIDER79d
    SEC Form 4 filed by Sr VP, General Counsel Shaw Kevin G.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022